A Retrospective Study on the Clinical Application of Compound Huangbai Liquid Topical Solution

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2024000310

Enrollment

Unknown

Registered

2024-08-27

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple different diseases

Interventions

Compound Huangbai liquid coating single drug group:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. In the target center: cases of prescription using compound Phellodiscus liquid coating; 2. Age 18-80 years old, male or female.

Exclusion criteria

Exclusion criteria: The researchers believe that the evaluation of the drug under study is not suitable for the collection of cases.

Design outcomes

Primary

Measure	Time frame
Blood routine serum procalcitonin (PCT) interleukin-6 (IL-6) C-reactive protein and other tests;	—

Secondary

Measure	Time frame
Score of wound edema degree pain score and wound healing time;	—

Countries

CHINA

Contacts

Public ContactLuo Wenji

The Fifth Affiliated Hospital of Sun Yat-sen University

1018693996@qq.com+86 139 0253 3429

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026